Generics Ask HHS To Include Rebate, Biosimilar Policies In Plan To Biden

Proposals to avoid rebate walls, mandate preferred formulary placement for biosimilars and share savings from biosimilars with doctors are among the many policies that the generic drug industry suggests HHS include in a drug-pricing report due to President Biden Monday (Aug. 23). The Association for Accessible Medicines also would like HHS to clarify rules for so-called skinny labels because the generic drug lobby says a recent court ruling makes the common tactic all but impossible for generic drug makers to...